JAGX vs JSPR

Jaguar Health, Inc. vs Jasper Therapeutics, Inc. — Valuation Comparison 2026

JAGX

Biotechnology
Jaguar Health, Inc.
Quality
4.2
out of 10
Value Trap
47
WARN
Price
$3.29
Last close
Models
5/13
Active
VS

JSPR

Biotechnology
Jasper Therapeutics, Inc.
Quality
3.5
out of 10
Value Trap
36
LOW
Price
$0.89
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType JAGX Fair ValueJAGX Upside JSPR Fair ValueJSPR Upside
Bayesian DCF Intrinsic $0.49 -44.6%
First Chicago Scenario $4.44 +27.9% $1.69 +99.4%
ML-RIV Intrinsic $0.66 -90.2% $0.03 -96.7%
Dynamic NAV Asset-Based $2.18 +144.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for JAGX vs JSPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JAGX vs JSPR — Which Stock Is More Undervalued?

JAGX scores higher with a 4.2/10 quality rating vs JSPR's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jaguar Health, Inc. (JAGX) and Jasper Therapeutics, Inc. (JSPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JAGX currently trades at $3.29 with a QOC of 4.2/10, while JSPR trades at $0.89 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).